GSK Reports P-III Trial (RUBY/ENGOT-EN6/GOG3031/NSGO) Results of Jemperli (dostarlimab) for Primary Advanced or Recurrent Endometrial Cancer
- The company highlighted an interim result from part 1 of the P-III trial evaluating Jemperli + CT vs CT + PBO which showed PFS improvement; 72% & 36% reduction in risk of disease progression or death in the dMMR/MSI-H & overall patient population
- In dMMR/MSI-H & overall population, PFS @24mos. (61.4% vs 18.1%) & (36.1% vs 18.1%); OS (83.3% vs 58.7%) in dMMR/MSI-H. In MMRp/MSS & overall population, PFS @24mos. (28.4% vs 18.8%) & (71.3% vs 56.0%); OS (67.7% vs 55.1%) in MMRp/MSS. The results were presented at ESMO & SGO; published in the NEJM
- In the overall population, 38.2% vs 15.4% had irAEs & TRAEs leading to treatment discontinuation (17.4% vs 9.3%) in the overall population. The regulatory submissions are expected to be planned in H1’23
Ref: phase-iii | Image: phase-iii
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.